OtherCHEMOTHERAPY/GENE THERAPY
Pharmacokinetics of G3139, a Phosphorothioate Oligodeoxynucleotide Antisense to bcl-2, after Intravenous Administration or Continuous Subcutaneous Infusion to Mice
Florence I. Raynaud, Rosanne M. Orr, Phyllis M. Goddard, Heidi A. Lacey, Helen Lancashire, Ian R. Judson, Terry Beck, Bob Bryan and Finbarr E. Cotter
Journal of Pharmacology and Experimental Therapeutics April 1997, 281 (1) 420-427;
Florence I. Raynaud
Rosanne M. Orr
Phyllis M. Goddard
Heidi A. Lacey
Helen Lancashire
Ian R. Judson
Terry Beck
Bob Bryan
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Journal of Pharmacology and Experimental Therapeutics
Vol. 281, Issue 1
1 Apr 1997
OtherCHEMOTHERAPY/GENE THERAPY
Pharmacokinetics of G3139, a Phosphorothioate Oligodeoxynucleotide Antisense to bcl-2, after Intravenous Administration or Continuous Subcutaneous Infusion to Mice
Florence I. Raynaud, Rosanne M. Orr, Phyllis M. Goddard, Heidi A. Lacey, Helen Lancashire, Ian R. Judson, Terry Beck, Bob Bryan and Finbarr E. Cotter
Journal of Pharmacology and Experimental Therapeutics April 1, 1997, 281 (1) 420-427;
OtherCHEMOTHERAPY/GENE THERAPY
Pharmacokinetics of G3139, a Phosphorothioate Oligodeoxynucleotide Antisense to bcl-2, after Intravenous Administration or Continuous Subcutaneous Infusion to Mice
Florence I. Raynaud, Rosanne M. Orr, Phyllis M. Goddard, Heidi A. Lacey, Helen Lancashire, Ian R. Judson, Terry Beck, Bob Bryan and Finbarr E. Cotter
Journal of Pharmacology and Experimental Therapeutics April 1, 1997, 281 (1) 420-427;
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement